oxaliplatin hospira 5 mg/ml - 50 mg
novapharma ltd - oxaliplatin 50 mg/vial - powder for solution for infusion - oxaliplatin - oxaliplatin in combination with 5- fluorouracil and folinic acid (fa) is indicated for : - adjuvant treatment of stage iii (duke's c) colon cancer after complete resection of the primary tumour .- treatment of metastatic colorectal cancer.
oxaliplatin hospira 5 mg/ml - 100 mg
novapharma ltd - oxaliplatin 100 mg/vial - powder for solution for infusion - oxaliplatin - oxaliplatin in combination with 5- fluorouracil and folinic acid (fa) is indicated for : - adjuvant treatment of stage iii (duke's c) colon cancer after complete resection of the primary tumour.- treatment of metastatic colorectal cancer.
oxaliplatin hospira 5 mg/ml
novapharma ltd - oxaliplatin 5 mg/ml - concentrate for solution for infusion - oxaliplatin - in combination with 5- fluorouracil and folinic acid (fa) oxaliplatin is indicated for: - adjuvant treatment of stage iii ( duke's c) colon cancer after complete resection of primary tumour - the treatment of metastatic colorectal cancer.
irinotecan injection 20 mg/ml
novapharma ltd - irinotecan (trihydrate) hydrochloride 20 mg/ml - concentrate for solution for infusion - irinotecan - irinotecan is indicated for the treatment of patients with metastatic colorectal cancer: - in combination with 5-fluorouracil and folinic acid in patients without prior chemotherapy for metastatic disease. - as a single agent in patients who have failed an astablished 5-fluorouracil containing treatment regimen. for the treatment of patients with small cell lung cancer. for the treatment of patients with gastric cancer.
nuelin sa tablet
inova pharmaceuticals (pty) ltd - tablet - see ingredients - each tablet contains anhydrous theophylline 250 mg
nuelin liquid
inova pharmaceuticals (pty) ltd - liquid - see ingredients - each 5,0 ml liquid contains theophylline 25,0 mg
pholtex junior syrup
inova pharmaceuticals (pty) ltd - syrup - see ingredients - each 5 ml contains pholcodine 5 mg
andolex analgesic lozenges
inova pharmaceuticals (pty) ltd - lozenges - see ingredients - each lozenge contains benzydamine hydrochloride 3,0 mg
andolex-c lozenges
inova pharmaceuticals (pty) ltd - lozenges - see ingredients - each lozenge contains benzydamine hydrochloride 3,00 mg cetylpyridinium chloride 1,33 mg
pholtex forte liquid
inova pharmaceuticals (pty) ltd - liquid - see ingredients - each 5 ml liquid contains pholcodine 15,0 mg